Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLKL | Q8NB16 | 4/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12066583 | 0.89 | MLKL (0.46) | MLKLLMNASMN1; SMN2KDM4EMAPT | |
| SCHEMBL14762836 | 0.81 | MLKL (0.48) | MLKLSCN10AKDM4ECNR1PDE2A | |
| SCHEMBL14762657 | 0.80 | MLKL (0.47) | MLKLSCN10ACNR1MAPTPDE2A | |
| SCHEMBL12065280 | 0.79 | MLKL (0.46) | MLKLSCN10ALMNASMN1; SMN2KDM4E | |
| SCHEMBL14770551 | 0.78 | LMNA (0.43) | LMNASMN1; SMN2KDM4EMAPT | |
| SCHEMBL12065635 | 0.78 | MLKL (0.68) | MLKLSCN10ASMN1; SMN2KDM4E | |
| SCHEMBL12065643 | 0.73 | SCN10A (0.46) | MLKLSCN10ACNR1PDE2ACYP1A2 | |
| SCHEMBL12066025 | 0.73 | SCN10A (0.45) | MLKLSCN10AKDM4EPDE2ACYP1A2 | |
| SCHEMBL12066548 | 0.72 | CYP2C9 (0.51) | MLKLSCN10AMAPTPDE2ACYP1A2 | |
| SCHEMBL14762773 | 0.72 | SCN10A (0.43) | MLKLSCN10ALMNAKDM4ECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096531-B2 | Fused imidazole derivative | TOA EIYO LTD. (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | TOA EIYO LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065896-A1 | FUSED IMIDAZOLE DERIVATIVE | CACNA1E, CACNA1G, CACNA1A | MLKL 2378/4885SCN10A 85/4885LMNA 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.